Hence, the validation of the prognostic value of PD-L1 or EGFR/HER2 immunoexpression in patients with lung cancer requires further studies with a larger sample size to establish their role in identifying the molecular subgroup for the purpose of target therapy and overall survival. This evidence concerns the gene EGFR and lung carcinoma.